BioBusiness

Articles

Sumitovant Bipharma has completed its acquisition of Myovant Sciences for approximately $1.7 billion.

Sumitovant Acquires Myovant for $1.7 Billion

CMO growth is focused on analytical testing, toxicity testing, and fill/finish operations.

Technology Advances in Outsourcing Services

Pharmapack Europe experts expect smaller and medium European packaging companies to grow or be acquired.

Pharmapack Experts Predict Increased Packaging Consolidations in 2023

The partnership led to Asimov licensing its clonal GMP HEK293 suspension cell line to CBM for pre-clinical and clinical production of viral vectors for its clients. 

Asimov and Center for Breakthrough Medicines Collaborate for Viral Vector Production

The merged company will operate under the name Ayala Pharmaceuticals and will target the development and commercialization of Ayala’s lead program, AL102, for the treatment of desmoid tumors. 

Advaxis, Ayala Pharmaceuticals Complete Merger

Snapdragon Chemistry concentrates in API batch and continuous flow process development, utilizing state-of-the-art automation technology and proprietary equipment to solve complex process and analytical development challenges.

Cambrex Acquires Snapdragon Chemistry

The Vault Quality Suite will help Adare simplify its quality operations across its sites in the United States, France, and Italy.

Adare Pharma Solutions Coordinating Quality with Veeva Vault Quality Suite

It is intended to identify the most prevalent and immunogenic targets in solid tumors by uniquely combining high-diversity target libraries with active machine learning.

Boehringer Ingelheim, 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

In addition, personnel, equipment, and facilities from the acquired companies will expand Reaction Biology’s presence in Germany while enabling its global customers to leverage Bioassay’s expansive portfolio of regulated clinical and commercial services.

Reaction Biology Acquires Bioassay GmbH for Increasing Large Molecule Capabilities 

Cytiva’s acquisition of CEVEC Pharmaceuticals strengthens the company’s cell line development and biomanufacturing capabilities.

Mergers and Acquisitions